Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.


Change log
Authors
Liu, Shiqin 
Shen, Michelle 
Hsu, En-Chi 
Zhang, Chiyuan Amy 
Garcia-Marques, Fernando 
Abstract

Distinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.

Description
Keywords
Biomarkers, Tumor, Carrier Proteins, Cytokines, Follow-Up Studies, Humans, Male, Prognosis, Prostatectomy, Prostatic Neoplasms, Survival Rate
Journal Title
Br J Cancer
Conference Name
Journal ISSN
0007-0920
1532-1827
Volume Title
124
Publisher
Springer Science and Business Media LLC